Bausch + Lomb Corporation (NYSE: BLCO) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.48 | Insider Own | - | Shs Outstand | 357.17M | Perf Week | -2.32% |
| Market Cap | 6.02B | Forward P/E | 15.33 | EPS next Y | 1.10 | Insider Trans | -0.02% | Shs Float | 45.55M | Perf Month | -3.44% |
| Enterprise Value | 10.77B | PEG | - | EPS next Q | 0.21 | Inst Own | 10.73% | Short Float | 0.95% | Perf Quarter | 13.32% |
| Income | -171.00M | P/S | 1.13 | EPS this Y | 265.39% | Inst Trans | - | Short Ratio | 8.11 | Perf Half Y | 4.21% |
| Sales | 5.32B | P/B | 0.93 | EPS next Y | 38.48% | ROA | -1.23% | Short Interest | 3.41M | Perf YTD | -1.35% |
| Book/sh | 18.04 | P/C | 16.40 | EPS next 5Y | 38.52% | ROE | -2.67% | 52W High | 18.92 -10.94% | Perf Year | 11.44% |
| Cash/sh | 1.03 | P/FCF | 43.90 | EPS past 3/5Y | - | ROIC | 3.16% | 52W Low | 13.77 22.37% | Perf 3Y | -4.64% |
| Dividend Est. | - | EV/EBITDA | 14.51 | Sales past 3/5Y | 10.62% 8.38% | Gross Margin | 57.23% | Volatility | 2.58% 2.53% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.02 | EPS Y/Y TTM | 46.67% | Oper. Margin | 7.14% | ATR (14) | 0.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.02 | Sales Y/Y TTM | 11.02% | Profit Margin | -3.21% | RSI (14) | 42.63 | Recom | 2.59 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.55 | EPS Q/Q | 128.57% | SMA20 | -3.36% | Beta | 0.99 | Target Price | 20.20 |
| Payout | 0.00% | Debt/Eq | 0.82 | Sales Q/Q | 8.69% | SMA50 | -0.42% | Rel Volume | 0.89 | Prev Close | 16.77 |
| Employees | 13,000 | LT Debt/Eq | 0.81 | Earnings | Nov 04 | SMA200 | 1.31% | Avg Volume | 404.50K | Price | 16.85 |
| IPO Date | May 06, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.65% 1.81% | Net Debt/EBITDA | 6.40 | Volume | 359,132 | Change | 0.48% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Initiated | Leerink | Outperform | $24 |
| Aug-03-26 | Reiterated | HC Wainwright & Co. | Buy | $20 → $21 |
| Jul-30-26 | Reiterated | UBS | Buy | $21 → $23 |
| Jul-28-26 | Initiated | UBS | Buy | $21 |
| Jul-06-26 | Reiterated | Evercore ISI Group | In Line | $18 → $17 |
| Apr-30-26 | Reiterated | Deutsche Bank | Hold | $18 → $16 |
| Feb-23-26 | Reiterated | HC Wainwright & Co. | Buy | $17 → $20 |
| Feb-19-26 | Reiterated | Stifel Nicolaus | $15 → $16 | |
| Feb-19-26 | Reiterated | Deutsche Bank | Hold | $15 → $18 |
| Feb-19-26 | Reiterated | Barclays | Equal Weight | $17 → $20 |
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,319 | 5,101 | 4,791 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,275 | 2,308 | 1,872 | — | — | — | — | — | — | |
| Gross Profit | 3,044 | 2,793 | 2,919 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2,224 | 2,234 | 2,082 | — | — | — | — | — | — | |
| Research and Development | 404 | 371 | 343 | — | — | — | — | — | — | |
| Other Operating Expense | 36 | 0 | 332 | — | — | — | — | — | — | |
| Operating Income | 380 | 188 | 162 | — | — | — | — | — | — | |
| Interest Expense | 396 | 431 | 399 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -49 | -74 | 3 | — | — | — | — | — | — | |
| Net Income Before Taxes | -65 | -317 | -234 | — | — | — | — | — | — | |
| Income Taxes | 98 | 35 | 71 | — | — | — | — | — | — | |
| Consolidated Net Income | -171 | -360 | -317 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -163 | -352 | -305 | — | — | — | — | — | — | |
| Net Income | -171 | -360 | -317 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.48 | -1.02 | -0.90 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.48 | -1.02 | -0.90 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.48 | -1.02 | -0.90 | — | — | — | — | — | — | |
| EBITDA | 742 | 535 | 601 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.13 | 1.19 | 1.33 | — | — | — | — | — | — | |
| Gross Margin | 57.23 | 54.75 | 60.93 | — | — | — | — | — | — | |
| Operating Margin | 7.14 | 3.69 | 3.38 | — | — | — | — | — | — | |
| Net Margin | -3.21 | -7.06 | -6.62 | — | — | — | — | — | — | |
| Shares Outstanding | 357 | 354 | 352 | — | — | — | — | — | — | |
| Market Capitalization | 6,015 | 6,046 | 6,357 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Munsch Frederick | SVP, Controller and CAO | Aug 10 '26 | Sale | 16.78 | 52,900 | 887,662 | 45,831 | Aug 12 |
| VON ESCHENBACH ANDREW C. | Director | Aug 07 '26 | Sale | 16.58 | 6,059 | 100,458 | 63,733 | Aug 10 |
| VON ESCHENBACH ANDREW C. | Director | Aug 06 '26 | Sale | 16.50 | 12,500 | 206,250 | 69,792 | Aug 10 |
| Bailey A Robert D | EVP & Chief Legal Officer | Mar 06 '26 | Buy | 17.15 | 14,600 | 250,332 | 231,890 | Mar 10 |
| Eldessouky Sam | EVP and CFO | Mar 06 '26 | Buy | 17.13 | 4,000 | 68,520 | 403,130 | Mar 10 |
| SAUNDERS BRENT L | CEO and Chairman of the Board | Mar 06 '26 | Buy | 17.14 | 14,700 | 251,958 | 966,575 | Mar 10 |
| Ross Thomas W. Sr. | Director | Mar 03 '26 | Buy | 17.68 | 4,500 | 79,556 | 64,891 | Mar 04 |
| Alfonso Eduardo | Director | Mar 02 '26 | Buy | 17.90 | 4,300 | 76,970 | 9,555 | Mar 03 |
| VON ESCHENBACH ANDREW C. | Director | Feb 27 '26 | Buy | 18.30 | 4,364 | 79,883 | 66,450 | Mar 03 |
| COLLIS STEVEN H | Director | Feb 23 '26 | Buy | 17.81 | 15,000 | 267,150 | 20,255 | Feb 24 |
| ROBERTSON RUSSEL C | Director | Feb 20 '26 | Buy | 17.90 | 4,400 | 78,760 | 72,407 | Feb 24 |
| Ling Karen | Director | Feb 19 '26 | Buy | 17.74 | 4,000 | 70,968 | 41,676 | Feb 23 |
| SAUNDERS BRENT L | CEO and Chairman of the Board | May 22 '25 | Buy | 11.28 | 22,000 | 248,072 | 719,156 | May 27 |
| VON ESCHENBACH ANDREW C. | Director | May 02 '25 | Buy | 11.76 | 1,695 | 19,925 | 41,748 | May 06 |
| SAUNDERS BRENT L | CEO and Chairman of the Board | Aug 05 '24 | Buy | 15.66 | 32,250 | 505,067 | 595,169 | Aug 07 |